Orthofix International (OFIX) Getting Somewhat Positive Press Coverage, Analysis Finds

News coverage about Orthofix International (NASDAQ:OFIX) has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Orthofix International earned a news impact score of 0.20 on Accern’s scale. Accern also assigned news articles about the medical device company an impact score of 46.5886707648761 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

OFIX has been the topic of a number of research analyst reports. BidaskClub raised shares of Orthofix International from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. ValuEngine raised shares of Orthofix International from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. SunTrust Banks increased their price target on shares of Orthofix International to $67.00 and gave the company a “buy” rating in a report on Monday, March 5th. TheStreet raised shares of Orthofix International from a “c+” rating to a “b” rating in a report on Tuesday, March 20th. Finally, Gabelli reissued a “buy” rating on shares of Orthofix International in a report on Wednesday, February 28th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $57.42.

Shares of NASDAQ:OFIX traded down $0.96 on Friday, reaching $57.85. 113,882 shares of the company’s stock were exchanged, compared to its average volume of 127,828. The firm has a market cap of $1,064.73, a PE ratio of 35.71, a PEG ratio of 3.25 and a beta of 0.24. Orthofix International has a twelve month low of $36.10 and a twelve month high of $61.00.

Orthofix International (NASDAQ:OFIX) last posted its quarterly earnings results on Monday, February 26th. The medical device company reported $0.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.02. The business had revenue of $116.90 million for the quarter, compared to analyst estimates of $116.93 million. Orthofix International had a net margin of 1.43% and a return on equity of 10.66%. The firm’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same quarter last year, the business posted $0.42 EPS. analysts forecast that Orthofix International will post 1.84 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/08/orthofix-international-ofix-receives-daily-media-sentiment-rating-of-0-20.html.

About Orthofix International

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.

Insider Buying and Selling by Quarter for Orthofix International (NASDAQ:OFIX)

Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply